Our commitment to safety communication

Verified safety updates from ongoing ocrelizumab clinical trials and post-marketing experience

As of March 2022, more than 250,000 patients with RMS and PPMS have started ocrelizumab globally, amounting to a total of more than 535,000 patient years1

>9,500 patients in clinical trials and open-label extension

>250,000 patients with post-marketing experience

 

Our commitment to safety communication

Verified safety updates from ongoing ocrelizumab clinical trials and post-marketing experience

As of March 2022, more than 250,000 patients with RMS and PPMS have started ocrelizumab globally, amounting to a total of more than 535,000 patient years1

>9,500 patients in clinical trials and open-label extension

>250,000 patients with post-marketing experience

 

References

1. Roche data on file: 31 March 2022, post-marketing experience; 31 March 2022, clinical trials data cut-off